Gastroenteropancreatic Neuroendocrine Tumors

Gastroenteropancreatic Neuroendocrine Tumors is the indication for 2 drugs in DrugBank. It is covered by 3 curated, structured indications.

Also known as: Gastro-enteropancreatic Neuroendocrine Tumor · Gastroenteropancreatic Neuroendocrine Tumor · Gastroenteral-Pancreatic Neuroendocrine Tumors · Gastro-Entero-Pancreatic Tumors (GEPs) · Gastroenteropancreatic Neuroendocrine Tumours
Classified under: Digestive System Diseases
Endocrine System Diseases
Neoplasms
Indicated drugs: Lutetium Lu 177 dotatate
Pentetreotide

Resolves to

Vocabularies

MeSHM0530111MedDRA10077559UMLSC2930967

What you can answer from here — as of October 23, 2026

2Indicated drugsWith each drug's targets and mechanism

Listed above

3Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

56Clinical trialsPhase, status and sponsor resolved per trial

1Drug reporting it as an adverse effectWith incidence where the label states it

Which approved drugs for Gastroenteropancreatic Neuroendocrine Tumors share a target, and which companies have late-stage candidates against it?

Create a free account or log in to explore the full data card.